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Abstract 
PATIENT EDUCATION IN  
 
LEFT VENTRICULAR NONCOMPACTION CARDIOMYOPATHY 
 
Tina Aldrich 
Under the Supervision of Patricia L. Bromley, Ph.D. 
 
  This paper sets forth the information needed to educate families about the genetic link of 
left ventricular noncompaction cardiomyopathy.  The current generation will have an opportunity 
to take advantage of the latest technologies and medications.  This paper describes the 
importance of echocardiogram testing of the asymptomatic patient and defines the medical 
terminology so the average family member can actually understand the contents.  The following 
parts are be covered:  clinical findings, physical symptoms, actions and possible treatment plans 
and hereditary responsibility.  An appendix is included with a patient advisory question and 
answer pamphlet.  Forms have been created to assist with patient tracking of cardiology 
appointments, medications, physicians, and family cardiac health history.  Also included are 
links to additional articles to read as well as support groups to join.   
 This paper examines this disease and explains what steps can be done to help keep the 
heart from unnecessary stress and trauma.  Through this increased awareness, early detection of 
progression and the prevention of complications, there will be a positive change in the 
management of left ventricular noncompaction cardiomyopathy. 
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Chapter One: Introduction 
 Many coaches, parents and the general population have heard stories of "healthy" teenage 
athletes dropping dead while competing in sporting events, or simply completing a workout with 
their teams.  This type of sudden death, while in action or at rest, can happen to children and 
adults alike and is often caused by cardiomyopathy.  In many of these sad cases, the deceased 
had no known heart problems and yet succumbed to a tachyarrhythmia which resulted in sudden 
cardiac death. This is a condition that is prevalent in the rare disease of left ventricular 
noncompaction (LVNC) cardiomyopathy (Suvarna, Deshmukh, & Hajela, 2009).   
 Some other people are actually diagnosed with a cardiomyopathy because of poor health 
conditions.  On July 30, 1998, Ronald A. Wyss was diagnosed with idiopathic cardiomyopathy.  
This diagnosis meant that the heart of this 32 year old patient was enlarged, weakened and not 
functioning properly, but there was no known reason for this heart condition.  The patient's 
father, Robert H. Wyss, had died suddenly at the age of 46, but was thought to have died from a 
blood clot stemming from a recent neck surgery.  The patient, Ronald A. Wyss, was given drug 
therapy to help control the symptoms and decrease the work load placed on the heart.  The drugs 
that were prescribed were:  blood thinners to control the possibility of blood clotting in the heart 
from stasis of the blood, beta blockers to slow the heart rate down so it did not work so hard and 
angiotensin-converting-enzyme inhibitors to reduce the workload of the heart.  The heart had an 
extremely low ejection fraction and some arrhythmias were noted.  After further testing, the 
patient was reclassified as having idiopathic dilated cardiomyopathy.  The patient was given an 
option for a defibrillator to be placed, but refused this.  In 1998 this patient was given a five to 
ten year life expectancy, but he suddenly died from an arrhythmia on October 16, 2004.  This 
patient was only 38 years old. 
  
2 
 
 The patient left behind two biological children, Brianna N. Wyss and Robert D. Wyss, 
ages seven and eight.  The possibility of a genetic link to this cardiomyopathy needed to be 
addressed to benefit the living relatives.  The autopsies and medical records of Ronald A. Wyss 
and Robert H. Wyss, along with the medical records of the paternal grandparents of the patient, 
Henry Wyss Jr. and Josephine B. Wyss, were obtained and researched.  This research was then 
brought to a cardiologist who aided in determining the problematic heart conditions that 
influenced the deaths of the patient's father and both paternal grandparents.  The first degree 
relatives were notified and the biological children started cardiac testing.  The tests for the 
children included EKG's, Holter monitors, echocardiograms and treadmill stress tests which were 
administered by a pediatric cardiologist.  These tests were performed every two years and all test 
results were normal.   
 The patient's only sibling, sister Carolyn Wyss Peters, was expecting a baby in July of 
2005.  During her childbirth she experienced heart problems and was diagnosed as having 
postpartum cardiomyopathy.  This cardiomyopathy did not go away months after childbirth and 
in 2009, at the age of 40, was finally classified correctly as left ventricular noncompaction 
cardiomyopathy, which is a genetic cardiomyopathy.  Ronald A. Wyss' autopsy and medical 
records were researched again and the diagnosis changed from idiopathic dilated 
cardiomyopathy to left ventricular noncompaction cardiomyopathy.  In 2011, the patient's 
children went to see this new cardiologist and were both classified as having left ventricular 
noncompaction morphology through echocardiogram testing.  The only three cousins in the 
Wyss family were also urged to check with this same doctor to verify heart health.  In 2011, two 
of the cousins were diagnosed as heart healthy, while the third, Daniel R. Sterk, was diagnosed 
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with left ventricular noncompaction cardiomyopathy at the age of 40.  This patient had 
experienced no prior physical symptoms. 
 Left ventricular noncompaction cardiomyopathy is a rare genetic heart disease that 
actually begins in the womb.  This means that all of these patients, including the "healthy" 
athletes, were actually born with this disease.  It is important to understand family health 
histories and be proactive in testing through echocardiograms and in verifying heart health with 
more than one cardiologist.  The earlier this condition is found, the more tools can be used to 
alleviate some of the strain that is placed on the heart.  In today's world of medical imaging and 
advances, all of these patients could have had an opportunity to be diagnosed while young and 
asymptomatic.  The idea is for the patient to live a healthy lifestyle and then to treat a patient 
immediately if they do indeed become symptomatic.  Early diagnosis would have taken off years 
of undue stress placed on the heart of these patients and made the prognosis for the disease 
better. 
 Left ventricular noncompaction cardiomyopathy, also called spongiform 
cardiomyopathy, is a rare congenital cardiomyopathy that affects both children and adults.  It 
results from the failure of myocardial development during embryogenesis (Suvarna et al., 2009).  
This is a condition that develops in the womb, affects the left ventricle and can manifest itself as 
an enlarged and weakened heart.  Because the left ventricle is affected, the common name for 
this disease is left ventricular noncompaction cardiomyopathy (Paterick, Gerber, Pradhan, Lindor 
& Tajik, 2010).  It is possible to be diagnosed with this condition at any age through the use of 
an echocardiogram, yet not to ever suffer from any of the symptoms associated with heart 
disease.  Likewise it is possible to suffer from severe heart failure, which even though the 
condition is present from birth, may only manifest itself later in life. 
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 Most people are diagnosed with LVNC cardiomyopathy because they are already 
symptomatic.  The physical symptoms may include breathlessness, fatigue, swelling of the 
ankles, racing heartbeat, limited physical capacity and exercise intolerance.  The clinical findings 
may include depression of systolic and diastolic function, poor pumping performance of the heart 
and an increased ratio of noncompacted wall to compacted wall of both heart ventricles.  Once 
the patients are diagnosed, the management of LVNC includes treatment of heart failure, 
arrhythmia, and thromboembolism.  Some patients may need an implanted internal defibrillator, 
and others may need cardiac transplantation (Hurst, 2002).  There is also the possibility of 
prescriptions or restrictions on physical activity (Paterick et al., 2010). 
 Left ventricular noncompaction cardiomyopathy was given its most recent name in 1990 
and the World Health Organization has it listed as an unclassified cardiomyopathy.  It was 
classified as a genetic cardiomyopathy by the American Heart Association in 2006 (Paterick, 
Umland, Jan, Ammar, Kramer, Khandheia, Seward & Tajik, 2012).  Due to LVNC 
cardiomyopathy being a relatively new disease, its impact on life expectancy is not very well 
understood (Espinola-Zavaleta, Soto, Castellanos, Játiva-Chávez & Keirns, 2007).  Most of the 
clinical studies on this disease deal with patients who are symptomatic and so are suffering from 
more severe forms of LVNC cardiomyopathy than might be found typically in the population.   
 Because LVNC cardiomyopathy is a genetic disease, immediate family members are 
being tested as a precaution.  This testing is turning up more supposedly healthy people with 
LVNC morphology/cardiomyopathy who are asymptomatic. The long-term prognosis for these 
people is currently unknown.  The early detection of asymptomatic LVNC cardiomyopathy 
places families in charge of being honest with and interested in their health histories and 
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supportive of echocardiogram testing.  A critical part of patient education is to have regular 
echocardiograms to monitor for the first signs of any clinical findings before physical symptoms 
are noticed.  This would allow the patient to be treated and monitored before the physical 
changes cause undue harm to the heart itself. 
 This research paper focuses on early detection for LVNC cardiomyopathy and the 
education that can be provided to families and patients so diagnosed.  Increasing the number of 
asymptomatic patients who can be monitored will result in better life expectancy and general 
wellness for those with the disease of LVNC cardiomyopathy.  
Statement of the Problem 
 The purpose of this project was to prepare materials which will be useful in educating 
and treating LVNC cardiomyopathy patients. 
Definition of Terms   
 Trabecula is a fibrous strand of connective tissue that supports the heart muscle in place.  
The characteristic appearance of numerous, excessively prominent trabeculae and deep 
intertrabecular recesses observed in one or more ventricular wall segment is characteristic 
in left ventricular noncompaction cardiomyopathy (Suvarna et al., 2009) 
 Left Ventricular Noncompaction (LVNC) Cardiomyopathy.  During heart development, 
the majority of the heart muscle is a sponge-like meshwork of interwoven myocardial 
fibers. As normal development progresses, these trabeculated structures undergo 
significant compaction that transforms them from spongy to solid. Noncompaction 
cardiomyopathy results when there is failure of compaction during this process. This 
disease is characterized anatomically by deep trabeculations in the ventricular wall, 
which define recesses communicating with the main ventricular chamber. Major clinical 
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correlates include systolic and diastolic dysfunction, associated at times with systemic 
embolic events (Espinola-Zavaleta et al., 2007). 
 Stasis is the state in which the normal flow of a body liquid stops,  for example the flow 
of blood through vessels (Taber's Medical Dictionary Online, 2000-2012).   
 Morphology refers to the form and structure of the internal parts like organs and bones 
(Taber's Medical Dictionary Online, 2000-2012).   
 Tachyarrhythmia is any cardiac rhythm disturbance in which the heart rate exceeds 100 
beats per minute (Taber's Medical Dictionary Online, 2000-2012). 
 Myocardial refers to the myocardium, the middle of the three layers forming the wall of 
the heart (Taber's Medical Dictionary Online, 2000-2012). 
 Embryogenesis is the process by which the embryo is formed and develops, until it 
develops into a fetus (Taber's Medical Dictionary Online, 2000-2012). 
 Echocardiogram is a visual record made by echocardiography which is the use of 
ultrasound to examine and measure the structure and functioning of the heart and to 
diagnose abnormalities and disease  (Merriam-Webster, Incorporated, 2012) 
 Thromboembolism is the blocking of a blood vessel by a particle that has broken away 
from a blood clot at its site of formation (Suvarna et al., 2009) 
Delimitations of Research 
 Left ventricular noncompaction research is limited because of the controversy over 
whether it is an actual disease entity. There is extensive prognosis overlap with dilated 
cardiomyopathy, apical hypertrophy, and hypertrophic cardiomyopathy (Paterick et al., 2010).  It 
takes an extremely knowledgeable cardiologist to know exactly what to look for in the 
echocardiogram readings to diagnose correctly.  This paper covers the importance of 
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echocardiogram diagnosis as well as addressing possible clinical findings and physical 
symptoms.  It focuses on working together with physicians and families to have an accurate 
treatment plan.  This paper does not address the technical results of echocardiograms or the 
possible complications in some of the treatment plans. 
Method of Approach 
 
 An extensive review of the disease LVNC cardiomyopathy was conducted.  A review of 
literature relating to research studies, illustrations of echocardiograms, postmortem 
examinations, magnetic resonance imaging, video clips, and actual cases of symptomatic and 
asymptomatic noncompaction patients was studied.  Actual echocardiograms performed on two 
patients were witnessed and e-mail and personal conversations with doctors specializing in this 
type of cardiomyopathy were conducted.  The findings were summarized and recommendations 
made.
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Chapter Two: Review of Related Literature 
Echocardiogram Diagnosis of Asymptomatic Patients 
 
 Left ventricular noncompaction cardiomyopathy has distinct structures and features that 
present themselves during the end stage of the myocardial growth process in the womb.  During 
the embryonic growth between five and eight weeks, intertrabecular recesses form such that they 
are in communication with the left ventricular endocardium. As normal cardiac growth and 
development progresses, myocardial compaction occurs and the intertrabecular recesses form 
into capillary beds.  Between 12 and 18 weeks in the womb, the process of compaction of the 
trabecular supporting connective tissue occurs.  This compaction adds to the proportion and 
thickness of the compact myocardium (Paterick et al., 2012). 
 It is hypothesized that the early ending of the compaction of the trabecular meshwork 
gives rise to LVNC in utero.  The result is a spongy meshwork of bilayered myocardium that has 
prominent trabeculae and deep intertrabecular recesses that communicate with the left ventricular 
cavity less effectively than a compacted myocardial would.  The gestational age at which the 
myocardium ceases to compact may determine the severity and extent of the LVNC (Paterick et 
al., 2012). 
 These distinct morphological features lend well to echocardiography for the diagnostic 
tool of choice.  The echocardiogram reveals the features of the bilayered myocardium, the 
prominent ventricular trabeculations and the deep intertrabecular recesses.  Widespread use of 
and advances in the technology of echocardiography and cardiac magnetic resonance imaging 
are increasing awareness of LVNC, and the cardiac magnetic resonance imaging is improving 
the ability to stage the severity of the disease (Paterick et al., 2012). 
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Clinical Findings  
 The use of the echocardiograms is valuable for two separate reasons.  First, it can give an 
asymptomatic patient peace of mind.  This means that the noncompacted myocardium, or spongy 
meshwork, can be traced to a small degree, but that the actual ratio of noncompacted to 
compacted myocardium is not at the stage that treatment is needed.  Secondly, there is no crystal 
clear answer as to whether the asymptomatic patient will ever have an actual onset of LVNC 
cardiomyopathy.  This disease entity requires close surveillance through echocardiograms so that 
if changes in the noncompacted to compacted myocardium ratio reach a clinically established 
number, treatment could begin immediately. 
 The change in the ratio of noncompacted to compacted myocardium is the basic sign for 
diagnosing that the asymptomatic patient now should be categorized and monitored for LVNC 
morphology/cardiomyopathy.  There is currently no intervention available to prevent the ratio 
from increasing.  Some of the clinical findings that can be measured are poor pumping 
performance, or ejection fraction, of the heart, the signs of thromboembolic events, ventricular 
arrhythmias, and the depression of systolic and diastolic function.  
 Ejection fraction is a measurement of the percentage of blood leaving the heart each time 
it contracts. During each heartbeat cycle, the heart contracts and relaxes. When the heart 
contracts it ejects blood from the two pumping chambers or ventricles. When the heart relaxes, 
the ventricles refill with blood. No matter how forceful the contraction, it does not empty all of 
the blood out of a ventricle. Because the left ventricle is the heart's main pumping chamber, 
ejection fraction is usually measured only in the left ventricle.  A normal left ventricle ejection 
fraction is generally greater than 55%. The ejection fraction may decrease if the heart muscle is 
weak due to LVNC cardiomyopathy or even long-standing uncontrolled high blood pressure 
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(Grogan, 2010).  One problem with a decreased ejection fraction can be the excessive amount of 
blood stasis in the ventricle where the heart function is depressed and does not move much which 
can cause the blood to clot.  Parts of this clot can then break off and could cause blockage of a 
blood vessel which could result in a stroke or peripheral embolization and is categorized as a 
thromboembolic event.  
 Another clinical finding that could be present is a ventricular arrhythmia.  These 
arrhythmias include ventricular tachycardia and ventricular fibrillation. Both are life threatening 
arrhythmias most commonly associated with heart attacks. When an abnormal heart rhythm 
comes from the lower chambers of your heart, the ventricle, it is called a ventricular arrhythmia. 
Rhythms of this type include ventricular tachycardia and ventricular fibrillation.  Both are life 
threatening arrhythmias most commonly associated with heart attacks or scarring of the heart 
muscle from a previous heart attack. 
 Ventricular tachycardia is a fast heart rhythm that occurs in one of the ventricles of your 
heart. It is like an electrical short circuit that races in a circle. In a ventricular tachycardia, the 
heart beat races around the circuit at rates from 150 to 250 beats per minute.  As the heart beats 
faster, it pumps less blood because there is not enough time for the heart to fill with blood 
between beats. If this fast heartbeat continues, the brain and body may not receive enough blood 
and oxygen. 
 Another type of ventricular arrhythmia is ventricular fibrillation.  Ventricular fibrillation 
originates from many different locations in the ventricles, each one trying to signal the heart to 
beat. In this case, the heart beats much faster than normal, sometimes over 300 beats per minute. 
The lower chambers quiver instead of contract, and very little, if any, blood is pumped from the 
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heart to the rest of the body. If a heart is in ventricular fibrillation, the person can become 
unconscious very quickly. The person might not remember anything that happened just before or 
during the episode. 
 If these irregular, fast heart rhythms continue for a length of time, the body will not get 
enough oxygen-carrying blood. Without oxygen, the brain and body tissues cannot function 
normally and die. 
 There are some symptoms of these arrhythmias.  If a person is experiencing a fast 
ventricular arrhythmia, they may feel as though their heart is skipping beats or fluttering. If the 
rhythm is very fast, they may experience fainting spells, blackouts, temporary blind spots, or 
dizziness. Eventually, the person may become unconscious and their heart might stop.  The 
diagnosis of ventricular arrhythmias, which are often unpredictable, can be challenging.  
Arrhythmias can be diagnosed through Holter monitors, electrocardiograms (EKG's) and 
treadmill stress tests. 
 Both ventricular tachycardia and ventricular fibrillation are life-threatening heart 
rhythms. In emergencies, paramedics or medical personnel can treat these arrhythmias with an 
automated external defibrillator (AED).  Long-term treatment options vary according to the type 
of arrhythmia and individual patient circumstances ("Ventricular arrhythmias -," 2012). 
Physical Symptoms 
 The most common symptoms of LVNC cardiomyopathy are the symptoms of heart 
failure. Some symptoms of heart failure include the following:  difficulty breathing, shortness of 
breath, chest pain, lightheadedness, limited physical capacity, exercise intolerance, swelling of 
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the lower extremities or edema, fatigue and distortion of the jugular veins. A chest x-ray usually 
shows congestion in the lungs from excess fluid buildup. Heart failure is a chronic condition that 
does not indicate LVNC cardiomyopathy unless accompanied by other symptoms. The additional 
symptoms that may indicate LVNC cardiomyopathy include heart rhythm disorders called 
arrhythmias, a very fast heart beat or tachycardia and an incidence of blood clots or embolisms. 
A person can experience these symptoms from birth or not have any symptoms until later in life, 
even though LVNC cardiomyopathy is a congenital defect (King, 2011). 
Actions and Possible Treatment Plans 
 Asymptomatic patients should follow a healthy lifestyle. They should minimize alcohol 
consumption, avoid recreational drugs, eliminate smoking and tobacco products, maintain a 
healthy weight, have a healthy nutritional plan including appropriate vitamins, fats and oils, 
obtain an appropriate amount of sleep and a consistent sleep pattern, exercise daily and create a 
low stress lifestyle.  It is also important to have regular physicals and echocardiograms.  The 
patient should live an emotionally healthy and active lifestyle and should not dwell on the fact 
that there could be heart complications in the future.  By having the patient stay on top of their 
echocardiograms and have them be honest with how their body feels, they should be confident 
about their healthy lifestyle and enjoy a normal life.  If the asymptomatic patient has a change in 
his or her heart health, the basic healthy lifestyle should continue to be followed but other 
treatment plans may be added. 
 There are several possible treatment plans for LVNC cardiomyopathy.  Drug therapy may 
include beta blockers, blood thinners, and angiotensin-converting-enzyme (ACE) inhibitors.  The 
patient may need to have an automatic internal cardioverter defibrillator inserted; some patients 
may be candidates for a heart transplant.  Each actual treatment plan is designed carefully and 
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uniquely for each individual patient tailored to their specific clinical results and physical 
symptoms.  The benefit for each of the treatments must outweigh the risks.   
 One type of medication that may be prescribed to help the heart perform more effectively 
is a beta-blocker.  One example of this type of medicine is a drug named carvedilol or Coreg.  
The weakened heart is wearing itself out, trying to make up for its weak pumping action by 
pumping more times per minute. Beta-blockers slow the heart rate, which lessens this wearing-
out process. Coreg also blocks alpha receptors in artery walls. This relaxes or expands the 
arteries, lowering the resistance against which the heart pumps, which is the blood pressure. 
Beta-blockers can also reduce some heart arrhythmias.  
 Another type of medication that may be used is an antiplatelet or blood thinning 
medication.  An example of this type of medication is Warfarin.  Another option is baby aspirin 
(Hitti, 2007).  These medications would help prevent the blood from clotting in the ventricles.  
The blood that is not being pumped back out of the heart due to a low ejection fraction and 
weakened heart pools in the ventricle.  With the addition of the blood thinning medication, the 
blood should not clot because the blood is now thinner.  This would eliminate or drastically 
decrease the chance of a piece of a blood clot breaking off and clogging an artery, causing a 
stroke or peripheral embolization.  The addition of a blood thinner helps decrease the likelihood 
of these thromboembolic events. 
  Angiotensin-converting-enzyme inhibitors are another category of drugs that can help 
with heart failure.  They are vasodilators; that means they dilate or widen the blood vessels to 
improve blood flow, which helps to decrease the amount of work the heart has to do. They also 
block some of the harmful substances in the blood.  One of these, angiotensin, is produced as a 
result of heart failure. Angiotensin is one of the most powerful vasoconstrictor in the body.  
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Angiotensin-converting-enzyme inhibitors are critical in the treatment of heart failure when 
systolic dysfunction is present and may also be prescribed for the treatment of diastolic 
dysfunction.  They are also used to control high blood pressure and prevent ongoing heart 
damage after a heart attack. An example of an ACE inhibitor is a drug called Lotensin. 
 If detected in the earlier stages, cardiomyopathy may be controlled with long-term drug 
therapy.  Occasionally antiarrhythmia medications or surgery are used in an effort to control or 
destroy the portion of heart tissue that causes the abnormal rhythms.  These treatments may be 
insufficient and may need to be augmented or replaced in treating the heart when dangerous 
arrhythmias must be regulated ("Ventricular arrhythmias -," 2012).  At this time the placement of 
an Automatic Implantable Cardioverter Defibrillator (AICD) may be added ("Children's 
cardiomyopathy foundation," 2012). The procedure involves implanting a small mechanical 
device under the skin of the chest with wire leads threaded through veins into the heart. It is 
considered minor surgery, requiring a short hospital stay. Once a defibrillator is inserted, it 
requires careful monitoring to determine when it needs to be replaced and to ensure that the 
electrical settings are correct. The decision to implant a defibrillator depends on the specific 
heart problem.  An automatic internal cardioverter defibrillator is used to detect and treat very 
fast, lethal heart rhythms. Often referred to as an "emergency room in the chest," an AICD will 
send a small electrical shock to the heart to restore a normal rhythm if a dangerously high heart 
rate occurs. It may benefit higher risk patients who have experienced serious episodes of 
fainting, been resuscitated from cardiac arrest, have experienced life threatening arrhythmias or 
are susceptible to sudden death ("Children's cardiomyopathy foundation," 2012). 
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 If all other methods of trying to control the heart function are not effective the patient 
may be a candidate for a heart transplant.  Heart transplantation is the procedure by which the 
failing heart is replaced with another heart from a suitable donor.   It is generally reserved for 
patients with end-stage congestive heart failure who are estimated to have less than 1 year to live 
without the transplant and who are not candidates for or have not been helped by conventional 
medical therapy (Tigen, Karaahmet, Kahveci, Mutlu & Basaran, 2008).  In addition, most 
candidates are excluded from other surgical options because of the poor condition of the heart.  
Attempts are made to stabilize the cardiac condition while the evaluation process is undertaken 
(Botta & Mancini, 2012). 
Hereditary Responsibility  
 Family screening is often not carried out because the focus is on attending to the patient 
with LVNC cardiomyopathy or grieving the death of a loved one who has succumbed to this 
disease. Identifying who else may be affected needs to be addressed.  In addition to assessing the 
risk to relatives and siblings, examining the ramifications for family planning is important.  
 Since LVNC cardiomyopathy can be inherited and present without any signs or 
symptoms, it is recommended that all first-degree relatives of a patient, such as parents, siblings, 
and children, be screened.  It is also advisable to screen grandparents, aunts, uncles, and cousins. 
This is especially the case if there is a family history of sudden infant death or sudden cardiac 
arrest. Even if there is no evidence of the disease, it is advisable to screen more than once with at 
least a couple of different cardiologists who specialize in cardiomyopathy. For children with an 
affected family member, parent or sibling, but without symptoms, an echocardiogram and EKG 
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should be regularly scheduled every 1 to 3 years prior to age 12 and then more frequently from 
age 12 to 21.  
 If by early adulthood there is no evidence of LVNC cardiomyopathy, it is unlikely that 
the condition will develop. However, those with a family history of cardiomyopathy may be 
advised to continue screening every 5 years throughout life even after the age of 21. These are 
general screening guidelines that may need to be adjusted on an individual basis by the 
evaluating cardiologist. Factors that typically influence the frequency of screening include: 1) 
type of cardiomyopathy diagnosed, 2) family history indicating the likelihood of familial 
cardiomyopathy and 3) clinical presentation profile of the affected family member ("Children's 
cardiomyopathy foundation," 2012). 
 It is not only important to share information and encourage testing of relatives, but also to 
look back at medical records and autopsies of relatives who have had sudden death.  This 
research can help provide a more accurate family cardiac history and aid in the present for 
correct diagnosis and treatment plans of the living relatives. 
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Chapter Three: Conclusions and Recommendations 
 In summary, this paper focuses on patient education in LVNC cardiomyopathy.  This 
paper describes the importance of echocardiogram testing of the asymptomatic patient and 
defines the medical terminology so the average family member can actually understand the 
contents.  The following parts were covered:  clinical findings, physical symptoms, actions and 
possible treatment plans and hereditary responsibility. 
 The existing literature on the topic leads to the following conclusions: through this 
increased awareness, early detection progression and the prevention of complications, there may 
be a positive change in the management of left ventricular noncompaction cardiomyopathy.  This 
awareness is critical to the detection and management of LVNC.  Patients need to know that they 
can live a long and healthy life with LVNC morphology/cardiomyopathy.  The patients should 
be proactive in treatments and appointments to ensure the latest medical options are being used 
in the patient's treatment plan. Obtaining a healthy lifestyle is extremely beneficial in the 
management of the disease. 
 Based on these conclusions, it is recommended that family members maintain open lines 
of communication regarding the status of the LVNC cardiomyopathy disease.  Patient educators 
should encourage family members to be tested and work together as a unit to aid the family in 
the diagnosis and treatment of this heart condition.  By utilizing the newest technologies in heart 
imaging, early detection can reveal the presence of the disease in asymptomatic patients.  This 
early detection, proper treatment and healthy lifestyle will likely increase the number of 
asymptomatic patients who can be monitored and should  result in better life expectancy and 
general wellness in living with the disease of LVNC cardiomyopathy.  
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Educational Readings and Support Groups 
 
 Informational readings are available to help the patient understand the disease of left 
ventricular noncompaction cardiomyopathy.  The patient and family are encouraged to continue 
to research the disease as well as communicate with other people that are impacted with LVNC 
morphology/cardiology.   
Education Readings and Support Groups for LVNC 
Cardiomyopathy 
Articles  
 The American Heart Association - http://www.heart.org/HEARTORG/ 
 The Cardiomyopathy Association - Left Ventricular Noncompaction  
http://www.cardiomyopathy.org/index.php?id=274  
 American Society of Echocardiography - LVNC - A 25-year Odyssey 
http://www.asecho.org/i4a/pages/index.cfm?pageID=4396  
 
Support Networks 
 
 Contact your health provider to help find support groups in your area 
 On-line chat groups for cardiomyopathy 
 Hospice to help the patient and family deal with a lifelong disease 
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Patient Advisory Pamphlet for LVNC Cardiomyopathy  
 
What is Cardiomyopathy? 
Cardiomyopathy is a disease of the heart 
muscle.   
 
What is LVNC Cardiomyopathy? 
Left ventricular noncompaction is a rare and 
primarily genetic cardiomyopathy affecting 
the left ventricle of the heart.  During 
growth and development in the womb, the 
majority of the heart muscle is a sponge-like 
meshwork of fibers.  As normal 
development progresses, these fibers 
undergo significant compaction that 
transforms them from spongy to solid.  
Noncompaction cardiomyopathy results 
when there is failure of this process of 
compaction.   
 
What are the symptoms? 
The symptoms caused by this condition are 
not specific and are mainly determined by 
how much the heart function is affected. 
Individuals who have the described 
structural features but normal performance 
of the heart may be entirely free of 
symptoms. 
 
Common symptoms associated with a 
reduced pumping performance of the heart 
include: 
 
 Breathlessness  
 Fatigue  
 Swelling of the lower extremities  
 Limited physical capacity and 
exercise intolerance 
 
 
 
How is it diagnosed? 
Echocardiogram - An ultrasound of your 
heart that allows your doctor to see each 
section of your heart, the thickness of the 
heart muscle, the major blood vessels 
connected to your heart, your heart valves, 
and the thin sack around your heart known 
as the pericardium.  This is perhaps the most 
valuable, painless test to determine the 
extent of heart disease. 
 
Electrocardiogram (EKG) - This test 
shows your doctor how your heart is beating 
and often whether there has been any 
damage or changes to your heart muscle. 
Electrical wires are placed on your chest, 
arms, and legs to record the electrical 
activity of your heart.  This procedure is also 
painless. 
 
Holter Monitors - By wearing a small 
portable electrocardiogram, your heart 
rhythm can be recorded over a 24 hour 
period.  It is a totally painless and safe test. 
 
Cardiac Magnetic Resonance Imaging - 
Cardiac MRI creates both still and moving 
pictures of your heart and major blood 
vessels. Doctors use cardiac MRI to get 
pictures of the beating heart and to look at 
its structure and function. These pictures can 
help them decide the best way to treat 
people who have heart problems.  This is a 
safe and pain free test. 
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How is it treated? 
Healthy Lifestyle 
 Minimize alcohol consumption 
 Avoid recreational drugs 
 Eliminate smoking and tobacco 
products 
 Maintain a healthy weight 
 Obtain appropriate sleep and sleep 
pattern 
 
Drug Therapy 
 Beta Blockers to relax the heart 
muscle.  This helps lower blood 
pressure and heart rate so that the 
heart does not have to work as hard. 
 Angiotensin-converting-enzyme 
(ACE) inhibitors to relax blood 
vessels and lower blood pressure.  
This helps the heart to pump more 
blood out to the body. 
 Blood Thinners to help keep the 
blood from clotting and prevent 
artery blockages and strokes. 
 
Procedures  
 Automatic Implantable Cardioverter 
Defibrillator (AICD) may be 
surgically inserted to treat abnormal 
heart rhythms. 
 Heart transplantation is a procedure 
by which the failing heart is replaced 
with another heart from a suitable 
donor.  This is reserved for patients 
who have not been helped by 
conventional therapy. 
 
Is there a cure? 
There is currently no medication to treat or 
cure LVNC cardiomyopathy.  Medication 
therapy treats the symptoms of the disease. 
Is this disease genetic? 
Yes, this disease is considered primarily a 
genetic cardiomyopathy.  It is recommended 
that all first-degree relatives of a patient 
such as parents, siblings, and children be 
screened by echocardiogram testing.  It is 
also advisable to screen grandparents, aunts, 
uncles, and cousins. 
 
Will my children inherit this disease 
from me? 
There is no way to know at this point 
whether this disease will travel to your 
children.  It is advisable to have your 
children's physicians be aware of this 
genetic cardiomyopathy and schedule 
regular echocardiograms to monitor for any 
signs of LVNC 
morphology/cardiomyopathy. 
 
What is the Prognosis? 
The prognosis for people affected by this 
condition is difficult to determine and must 
be individualized. In general prognosis is 
associated with the degree of cardiac 
impairment. In severe cases it seems to be 
no different than the prognosis for any other 
heart failure.  But increased awareness, the 
early detection of progression and the 
prevention of complications can really make 
the difference in improving prognosis. 
Knowledge is power! 
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Patient Cardiologist Appointments 
 
 The patient should list cardiologist appointments and any referring doctor in the chart 
provided.  This is a chart that should be copied off and updated.  The patient should fill in each 
visit to help remember what has been done.  This aids in planning for further tests and dates.  It 
will help the patient be more in control of the disease and accountable for maintaining their own 
body. 
Patient Cardiologist Visit and Follow-Up 
 
  Date:    
Physician:    
Referring Physician:    
Reason for Visit:    
Comments:    
 
   Problems since last visit: 
 
 
 
 
 
       
  Echocardiogram: 
 
Other Procedures: 
 
 
 
   Next appointment date: 
Next appointment plan: 
 
 
 
 
       
  Medication Changes: 
 
 
 
 
 
   Weight: 
Blood Pressure: 
Cholesterol: 
Alcohol Use: 
Tobacco Use: 
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Patient Current Medication Information  
 
 The patient should list any current or newly-prescribed medications.  This listing will 
help maintain accurate records of dosages and reasons for taking a medication.  In the comment 
section the patient should log any reactions, positive or negative.  The patient is advised to make 
sure pharmacies have a complete listing of the patient’s medications. 
Patient Current Medication Information  
  Medication name:    
Medication purpose:    
Dosage:   
Prescribing doctor:    
Comments:    
Start Date: 
 
   Medication name:    
Medication purpose:    
Dosage:    
Prescribing doctor:    
Comments:    
Start Date: 
 
       
  Medication name:    
Medication purpose:    
Dosage:    
Prescribing doctor:    
Comments:    
Start Date: 
 
   Medication name:    
Medication purpose:    
Dosage:    
Prescribing doctor:    
Comments:   
Start Date:  
 
       
  Medication name:    
Medication purpose:    
Dosage:    
Prescribing doctor:    
Comments:    
Start Date: 
 
   Medication name:    
Medication purpose:    
Dosage:    
Prescribing doctor:    
Comments:    
Start Date: 
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Patient Medication History 
 
 The patient should list any medications that have been prescribed but usage has been 
discontinued.  This listing will help the patient maintain accurate records of dosages and reasons 
for taking a medication.  In the comment section the patient should log any reactions, positive or 
negative.  Pharmacies and doctors should be notified when a medication has been discontinued. 
Patient Medication History 
  Medication name:    
Medication purpose:    
Dosage:   
Prescribing doctor:    
Comments:    
End Date: 
 
   Medication name:    
Medication purpose:    
Dosage:    
Prescribing doctor:    
Comments:    
End Date: 
 
       
  Medication name:    
Medication purpose:    
Dosage:    
Prescribing doctor:    
Comments:    
End Date: 
 
   Medication name:    
Medication purpose:    
Dosage:    
Prescribing doctor:    
Comments:    
End Date: 
 
       
  Medication name:    
Medication purpose:    
Dosage:    
Prescribing doctor:    
Comments:    
End Date: 
 
   Medication name:    
Medication purpose:    
Dosage:    
Prescribing doctor:    
Comments:  
End Date:   
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Patient Physician History 
 
 The patient should list any physicians that are seen, and their location and contact 
information.  This list should include primary doctors, cardiologists, and doctors seen for second 
opinions. It should include any changes of doctors due to insurance changes.  This listing will 
help maintain accurate record locations to share appropriate health history with other providers. 
Patient Physician Contact Information 
 
  Physician name:    
Specialty:    
Purpose of Visit:    
Location:    
Contact Information:    
 
   Physician name:    
Specialty:   
Purpose of Visit:    
Location:    
Contact Information:    
 
       
  Physician name:    
Specialty:   
Purpose of Visit:    
Location:    
Contact Information:    
 
   Physician name:    
Specialty:   
Purpose of Visit:    
Location:    
Contact Information:    
 
       
  Physician name:    
Specialty:   
Purpose of Visit:    
Location:    
Contact Information:    
 
   Physician name:    
Specialty:   
Purpose of Visit:    
Location:    
Contact Information:    
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Patient Family Cardiology Health History  
 
 This chart provides the opportunity for the patient to talk to family members and be open 
about their cardiac health histories.  Everything should be listed in one place to refer back to and 
share with doctors. 
Patient Family Cardiology Health History 
Relation Alive 
Deceased 
Heart 
Disease 
High 
Blood 
Pressure 
High 
Cholesterol 
Arrhythmias Sudden 
Death 
Mother 
 
      
Father 
 
      
Siblings: 
 
      
 
 
      
 
 
      
 
 
      
Paternal 
Grandfather 
      
Paternal 
Grandmother 
      
Maternal 
Grandfather 
      
Maternal 
Grandmother 
      
Paternal 
Aunt 
      
Paternal 
Uncle 
      
Maternal 
Aunt 
      
Maternal 
Uncle 
      
Other       
 
